314 related articles for article (PubMed ID: 18546865)
21. Characterization of prostatic neuroendocrine cell line established from neuroendocrine carcinoma of transgenic mouse allograft model.
Uchida K; Masumori N; Takahashi A; Itoh N; Tsukamoto T
Prostate; 2005 Jan; 62(1):40-8. PubMed ID: 15389815
[TBL] [Abstract][Full Text] [Related]
22. [Neuroendocrine tumors of the prostate].
Bours AF; Jorion JL; Donnay M; Ledent G; Van Ruyssevelt C
Acta Urol Belg; 1993 Sep; 61(3):13-6. PubMed ID: 8256680
[TBL] [Abstract][Full Text] [Related]
23. Large cell neuroendocrine carcinoma of the tongue base: case report of an unusual location with immunohistochemical analysis.
Kusafuka K; Asano R; Kamijo T; Iida Y; Onitsuka T; Kameya T; Nakajima T
Int J Oral Maxillofac Surg; 2009 Mar; 38(3):296-9. PubMed ID: 19167190
[TBL] [Abstract][Full Text] [Related]
24. [Orbital metastasis of a prostatic cancer. A therapeutic emergency].
Aubert J; Dore B; Bon D
Prog Urol; 1997 Feb; 7(1):81-4. PubMed ID: 9116744
[TBL] [Abstract][Full Text] [Related]
25. Delayed diagnosis of prostate cancer with neuroendocrine differentiation after laser TURP.
Meeks JJ; Habermacher GM; Le B; Smith ND
Urology; 2008 Oct; 72(4):948.e11-2. PubMed ID: 18342929
[TBL] [Abstract][Full Text] [Related]
26. [Orbital metastasis of prostatic carcinoma].
El Mejjad A; Jouhadi H; Fekak H; Rabii R; Bennani S; Benider A; El Mrini M
Prog Urol; 2005 Feb; 15(1):85-8. PubMed ID: 15822401
[TBL] [Abstract][Full Text] [Related]
27. Paraneoplastic cholestasis associated with prostate carcinoma.
Koruk M; Büyükberber M; Savaş C; Kadayifçi A
Turk J Gastroenterol; 2004 Mar; 15(1):53-5. PubMed ID: 15264123
[TBL] [Abstract][Full Text] [Related]
28. [Orbital metastasis of prostatic cancer. Clinical and therapeutic aspects. Apropos of a case (clinical case)].
Aubert J; Irani J; Saint-Blancat P
Chirurgie; 1997 Jan; 121(9-10):672-5. PubMed ID: 9138330
[TBL] [Abstract][Full Text] [Related]
29. Neuroendocrine differentiation in prostate cancer: a sheep in wolf's clothing?
Slovin SF
Nat Clin Pract Urol; 2006 Mar; 3(3):138-44. PubMed ID: 16528286
[TBL] [Abstract][Full Text] [Related]
30. Metastatic large-cell neuroendocrine prostate carcinoma: successful treatment with androgen deprivation therapy.
Azad AA; Jones EC; Chi KN
Clin Genitourin Cancer; 2014 Aug; 12(4):e151-3. PubMed ID: 24787970
[No Abstract] [Full Text] [Related]
31. [Recent data about prostatic carcinoma (author's transl)].
Coune A
Rev Med Brux; 1980 May; 1(5):311-4. PubMed ID: 7466030
[No Abstract] [Full Text] [Related]
32. Large-cell neuroendocrine carcinoma of prostate. Case report.
Moratalla Charcos LM; Pastor Navarro T; Cortes Vizcaino V; Osca Garcia JM; Gil Salom M
Arch Esp Urol; 2013 May; 66(4):368-71. PubMed ID: 23676541
[TBL] [Abstract][Full Text] [Related]
33. Can conception of prostate cancer stem cells influence treatment dedicated to patients with disseminated disease?
Drewa T; Styczynski J
Med Hypotheses; 2008 Nov; 71(5):694-9. PubMed ID: 18706770
[TBL] [Abstract][Full Text] [Related]
34. Predictors of clinical metastasis in prostate cancer patients receiving androgen deprivation therapy: results from CaPSURE.
Abouassaly R; Paciorek A; Ryan CJ; Carroll PR; Klein EA
Cancer; 2009 Oct; 115(19):4470-6. PubMed ID: 19637339
[TBL] [Abstract][Full Text] [Related]
35. [Histological classification of prostate cancer with clinicopathological implication].
Harada M
Nihon Rinsho; 2002 Dec; 60 Suppl 11():76-81. PubMed ID: 12599549
[No Abstract] [Full Text] [Related]
36. Hormonal approaches in prostate cancer: application in the contemporary prostate cancer patient.
Beekman KW; Hussain M
Urol Oncol; 2008; 26(4):415-9. PubMed ID: 18593620
[TBL] [Abstract][Full Text] [Related]
37. Large cell differentiation of metastatic prostate cancer after androgen deprivation therapy.
Patel R; Faiena I; Geltzeiler J
Can J Urol; 2015 Apr; 22(2):7752-4. PubMed ID: 25891342
[TBL] [Abstract][Full Text] [Related]
38. Prognostic significance of neuroendocrine differentiation in prostate adenocarcinoma.
Sagnak L; Topaloglu H; Ozok U; Ersoy H
Clin Genitourin Cancer; 2011 Dec; 9(2):73-80. PubMed ID: 22035833
[TBL] [Abstract][Full Text] [Related]
39. Selective expression of CD44, a putative prostate cancer stem cell marker, in neuroendocrine tumor cells of human prostate cancer.
Palapattu GS; Wu C; Silvers CR; Martin HB; Williams K; Salamone L; Bushnell T; Huang LS; Yang Q; Huang J
Prostate; 2009 May; 69(7):787-98. PubMed ID: 19189306
[TBL] [Abstract][Full Text] [Related]
40. Androgen-deprivation therapy-induced aggressive prostate cancer with neuroendocrine differentiation.
Lipianskaya J; Cohen A; Chen CJ; Hsia E; Squires J; Li Z; Zhang Y; Li W; Chen X; Xu H; Huang J
Asian J Androl; 2014; 16(4):541-4. PubMed ID: 24589459
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
